Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.28
A's Cash to Debt is ranked higher than
65% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.73 vs. A: 1.28 )
A' s 10-Year Cash to Debt Range
Min: 0.63   Max: No Debt
Current: 1.28

Equity to Asset 0.56
A's Equity to Asset is ranked higher than
69% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.62 vs. A: 0.56 )
A' s 10-Year Equity to Asset Range
Min: 0.31   Max: 0.71
Current: 0.56

0.31
0.71
Interest Coverage 7.35
A's Interest Coverage is ranked higher than
54% of the 143 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 257.77 vs. A: 7.35 )
A' s 10-Year Interest Coverage Range
Min: 0.53   Max: 9999.99
Current: 7.35

0.53
9999.99
F-Score: 7
Z-Score: 5.09
M-Score: -2.73
WACC vs ROIC
7.99%
9.80%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 11.50
A's Operating margin (%) is ranked higher than
88% of the 249 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.55 vs. A: 11.50 )
A' s 10-Year Operating margin (%) Range
Min: -26.74   Max: 16.32
Current: 11.5

-26.74
16.32
Net-margin (%) 6.02
A's Net-margin (%) is ranked higher than
84% of the 249 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.38 vs. A: 6.02 )
A' s 10-Year Net-margin (%) Range
Min: -46.06   Max: 66.5
Current: 6.02

-46.06
66.5
ROE (%) 7.26
A's ROE (%) is ranked higher than
81% of the 233 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.03 vs. A: 7.26 )
A' s 10-Year ROE (%) Range
Min: -55.24   Max: 85.57
Current: 7.26

-55.24
85.57
ROA (%) 3.78
A's ROA (%) is ranked higher than
82% of the 257 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.48 vs. A: 3.78 )
A' s 10-Year ROA (%) Range
Min: -28.39   Max: 46.84
Current: 3.78

-28.39
46.84
ROC (Joel Greenblatt) (%) 40.95
A's ROC (Joel Greenblatt) (%) is ranked higher than
89% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.08 vs. A: 40.95 )
A' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -54.39   Max: 71.3
Current: 40.95

-54.39
71.3
Revenue Growth (3Y)(%) 3.50
A's Revenue Growth (3Y)(%) is ranked higher than
72% of the 190 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. A: 3.50 )
A' s 10-Year Revenue Growth (3Y)(%) Range
Min: -22.8   Max: 18.4
Current: 3.5

-22.8
18.4
EBITDA Growth (3Y)(%) -4.30
A's EBITDA Growth (3Y)(%) is ranked higher than
66% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.50 vs. A: -4.30 )
A' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -27.7   Max: 76.8
Current: -4.3

-27.7
76.8
EPS Growth (3Y)(%) -19.40
A's EPS Growth (3Y)(%) is ranked higher than
62% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.60 vs. A: -19.40 )
A' s 10-Year EPS Growth (3Y)(%) Range
Min: -19.4   Max: 135.6
Current: -19.4

-19.4
135.6
» A's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

A Guru Trades in Q1 2014

Paul Tudor Jones 6,156 sh (New)
Signature Select Canadian Fund 191,600 sh (New)
David Dreman 2,134 sh (+288.00%)
Steven Cohen 128,546 sh (+183.62%)
Caxton Associates 60,000 sh (unchged)
Ron Baron 26,000 sh (unchged)
Vanguard Health Care Fund 5,624,200 sh (unchged)
John Hussman 313,000 sh (unchged)
George Soros Sold Out
Jim Simons Sold Out
Caxton Associates Sold Out
Robert Olstein Sold Out
Pioneer Investments Sold Out
Brian Rogers Sold Out
PRIMECAP Management 94,009 sh (-0.63%)
Chris Davis 3,246,884 sh (-9.43%)
Richard Snow 649,036 sh (-46.12%)
» More
Q2 2014

A Guru Trades in Q2 2014

John Keeley 46,640 sh (New)
Jean-Marie Eveillard 831,224 sh (New)
Paul Tudor Jones 128,579 sh (+1988.68%)
David Dreman 2,332 sh (+9.28%)
Vanguard Health Care Fund 5,624,200 sh (unchged)
Ron Baron 26,000 sh (unchged)
John Hussman Sold Out
Richard Snow Sold Out
PRIMECAP Management 91,717 sh (-2.44%)
Chris Davis 2,991,923 sh (-7.85%)
» More
Q3 2014

A Guru Trades in Q3 2014

Jim Simons 187,500 sh (New)
John Burbank 35,000 sh (New)
Joel Greenblatt 372,199 sh (New)
PRIMECAP Management 2,813,589 sh (+2967.69%)
Paul Tudor Jones 209,138 sh (+62.65%)
Jean-Marie Eveillard 1,129,300 sh (+35.86%)
Signature Select Canadian Fund 257,600 sh (+34.45%)
John Keeley 48,840 sh (+4.72%)
David Dreman 2,411 sh (+3.39%)
Ron Baron 26,000 sh (unchged)
Vanguard Health Care Fund 5,624,200 sh (unchged)
Chris Davis 2,980,262 sh (-0.39%)
» More
Q4 2014

A Guru Trades in Q4 2014

Jeremy Grantham 110,000 sh (New)
Jim Simons 1,315,200 sh (+601.44%)
PRIMECAP Management 5,666,300 sh (+101.39%)
John Keeley 70,660 sh (+44.68%)
Ron Baron 33,900 sh (+30.38%)
Vanguard Health Care Fund 5,624,200 sh (unchged)
David Dreman Sold Out
Jean-Marie Eveillard Sold Out
John Burbank Sold Out
Chris Davis 2,969,653 sh (-0.36%)
Paul Tudor Jones 154,856 sh (-25.96%)
Joel Greenblatt 5,790 sh (-98.44%)
» More
» Details

Insider Trades

Latest Guru Trades with A

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 37.50
A's P/E(ttm) is ranked higher than
85% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. A: 37.50 )
A' s 10-Year P/E(ttm) Range
Min: 2.74   Max: 48.25
Current: 37.5

2.74
48.25
Forward P/E 20.88
A's Forward P/E is ranked higher than
88% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. A: 20.88 )
N/A
PE(NRI) 34.00
A's PE(NRI) is ranked higher than
87% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. A: 34.00 )
A' s 10-Year PE(NRI) Range
Min: 5.2   Max: 64.99
Current: 34

5.2
64.99
P/B 3.30
A's P/B is ranked higher than
75% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.82 vs. A: 3.30 )
A' s 10-Year P/B Range
Min: 1.21   Max: 3.47
Current: 3.3

1.21
3.47
P/S 2.20
A's P/S is ranked higher than
80% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.63 vs. A: 2.20 )
A' s 10-Year P/S Range
Min: 0.59   Max: 3.9
Current: 2.2

0.59
3.9
PFCF 46.20
A's PFCF is ranked higher than
82% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. A: 46.20 )
A' s 10-Year PFCF Range
Min: 5.38   Max: 72.59
Current: 46.2

5.38
72.59
POCF 27.97
A's POCF is ranked higher than
81% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 431.57 vs. A: 27.97 )
A' s 10-Year POCF Range
Min: 4.31   Max: 32.03
Current: 27.97

4.31
32.03
EV-to-EBIT 18.34
A's EV-to-EBIT is ranked higher than
88% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. A: 18.34 )
A' s 10-Year EV-to-EBIT Range
Min: -143.5   Max: 305.7
Current: 18.34

-143.5
305.7
PEG 1.21
A's PEG is ranked higher than
98% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. A: 1.21 )
A' s 10-Year PEG Range
Min: 0.08   Max: 7.44
Current: 1.21

0.08
7.44
Shiller P/E 21.10
A's Shiller P/E is ranked higher than
96% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. A: 21.10 )
A' s 10-Year Shiller P/E Range
Min: 6.42   Max: 87.11
Current: 21.1

6.42
87.11
Current Ratio 3.94
A's Current Ratio is ranked higher than
82% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.64 vs. A: 3.94 )
A' s 10-Year Current Ratio Range
Min: 1.61   Max: 3.94
Current: 3.94

1.61
3.94
Quick Ratio 3.33
A's Quick Ratio is ranked higher than
81% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. A: 3.33 )
A' s 10-Year Quick Ratio Range
Min: 1.04   Max: 3.33
Current: 3.33

1.04
3.33
Days Inventory 115.65
A's Days Inventory is ranked higher than
72% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 131.99 vs. A: 115.65 )
A' s 10-Year Days Inventory Range
Min: 91.25   Max: 151.03
Current: 115.65

91.25
151.03
Days Sales Outstanding 35.47
A's Days Sales Outstanding is ranked higher than
91% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 74.31 vs. A: 35.47 )
A' s 10-Year Days Sales Outstanding Range
Min: 42.47   Max: 88.72
Current: 35.47

42.47
88.72

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.10
A's Dividend Yield is ranked lower than
56% of the 85 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.33 vs. A: 1.10 )
A' s 10-Year Dividend Yield Range
Min: 0.31   Max: 1.42
Current: 1.1

0.31
1.42
Dividend Payout 0.35
A's Dividend Payout is ranked higher than
90% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. A: 0.35 )
A' s 10-Year Dividend Payout Range
Min: 0.09   Max: 1.94
Current: 0.35

0.09
1.94
Yield on cost (5-Year) 1.10
A's Yield on cost (5-Year) is ranked lower than
58% of the 88 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.32 vs. A: 1.10 )
A' s 10-Year Yield on cost (5-Year) Range
Min: 0.31   Max: 1.42
Current: 1.1

0.31
1.42
Share Buyback Rate 1.60
A's Share Buyback Rate is ranked higher than
94% of the 173 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.50 vs. A: 1.60 )
A' s 10-Year Share Buyback Rate Range
Min: 9.5   Max: -7
Current: 1.6

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 10.60
A's Price/Tangible Book is ranked higher than
64% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.60 vs. A: 10.60 )
A' s 10-Year Price/Tangible Book Range
Min: 1.1   Max: 9.14
Current: 10.6

1.1
9.14
Price/DCF (Projected) 1.00
A's Price/DCF (Projected) is ranked higher than
98% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. A: 1.00 )
A' s 10-Year Price/DCF (Projected) Range
Min: 0.62   Max: 2.97
Current: 1

0.62
2.97
Price/Median PS Value 1.20
A's Price/Median PS Value is ranked higher than
72% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.30 vs. A: 1.20 )
A' s 10-Year Price/Median PS Value Range
Min: 0.4   Max: 1.7
Current: 1.2

0.4
1.7
Price/Peter Lynch Fair Value 4.40
A's Price/Peter Lynch Fair Value is ranked higher than
90% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. A: 4.40 )
A' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.3   Max: 3.96
Current: 4.4

0.3
3.96
Price/Graham Number 4.00
A's Price/Graham Number is ranked higher than
85% of the 283 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.00 vs. A: 4.00 )
A' s 10-Year Price/Graham Number Range
Min: 0.78   Max: 3.62
Current: 4

0.78
3.62
Earnings Yield (Greenblatt) 5.40
A's Earnings Yield (Greenblatt) is ranked higher than
89% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. A: 5.40 )
A' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 17.1
Current: 5.4

0.3
17.1
Forward Rate of Return (Yacktman) 13.58
A's Forward Rate of Return (Yacktman) is ranked higher than
79% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.73 vs. A: 13.58 )
A' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -0.8   Max: 78.6
Current: 13.58

-0.8
78.6

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:ROP, GRMN, HXGBY, TRMB, NANO » details
Traded in other countries:AG8.Germany,
Agilent Technologies Inc was incorporated in Delaware in May 1999. The Company is a measurement company, providing core bio-analytical and electronic measurement solutions to the life sciences, chemical analysis, communications and electronics industries. The four operating segments are Life sciences business, Chemical Analysis Business, Diagnostics and Genomics Business and Electronic Measurement Business. Life sciences business provides application-focused solutions that include instruments, software, consumables, and services that enable customers to identify, quantify and analyze the physical and biological properties of substances and products. Key product categories in life sciences include: liquid chromatography systems, columns and components; liquid chromatography mass spectrometry systems; laboratory software and informatics systems; laboratory automation and robotic systems; dissolution testing; nucleic acid solutions; Nuclear Magnetic Resonance ; Magnetic Resonance Imaging and X-Ray Diffraction systems and services and support for the aforementioned products. The Chemical Analysis business provides application-focused solutions that include instruments, software, consumables, and services that enable customers to identify, quantify and analyze the physical and biological properties of substances and products. Key product categories in chemical analysis include: gas chromatography systems, columns and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; software and data systems; vacuum pumps and measurement technologies; services and support for its products. Diagnostics and genomics business provides solutions that include reagents, instruments, software and consumables that enable customers in the clinical and life sciences research areas to interrogate samples at the molecular level. Its offerings include immunohistochemistry, In Situ Hybridization, Hematoxylin and Eosin Staining, special staining, DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, as well as automated gel electrophoresis-based sample analysis systems. Electronic Measurement Business provides electronic measurement instruments and systems, software design tools and related services that are used in the design, development, manufacture, installation, deployment and operation of electronics equipment, and microscopy products. Related services include start-up assistance, instrument productivity and application services and instrument calibration and repair. The Company's primary competitors are Bruker Corp., Danaher Corporation, Thermo Fisher Scientific Inc., Waters Corp, PerkinElmer Inc., Shimadzu Corporation, Ventana Medi
» More Articles for A

Headlines

Articles On GuruFocus.com
Agilent Has Focused on Several Strategic Actions Mar 20 2014 
Chris Davis' Davis Funds 2013 Portfolio Managers Update Feb 27 2014 
$500 Billion Manager Brian Rogers’ About-Face on Apple Inc. Dec 02 2013 
The Best Yielding Ex-Dividend Stocks on March 28, 2013 Mar 27 2013 
comment on A Mar 15 2013 
comment on A Mar 15 2013 
Edward Owens’ 3 Biggest Stock Increases Feb 05 2013 
My 4 Favorites of the 32 Stocks with Dividend Growth from Last Week Jan 20 2013 
comment on A Sep 20 2012 
Value Investor Robert Olstein: Market Is Overreacting and His Top Picks Aug 10 2012 

More From Our Partners
The March Madness 'Sweet 16' of Stocks - Analyst Blog Mar 26 2015 - ZACKS

More From Other Websites
Rigaku Corp. and Agilent Technologies Announce Rigaku to Acquire Agilent's X-Ray Diffraction... Mar 30 2015
Rigaku Corp. and Agilent Technologies Announce Rigaku to Acquire Agilent’s X-Ray Diffraction... Mar 30 2015
Rigaku Corp. and Agilent Technologies Announce Rigaku to Acquire Agilent’s X-Ray Diffraction... Mar 30 2015
The March Madness 'Sweet 16' of Stocks - Analyst Blog Mar 26 2015
Agilent Technologies Receives Award for Outstanding Customer Service Mar 25 2015
Agilent Technologies Receives Award for Outstanding Customer Service Mar 25 2015
Dako, an Agilent Technologies Company, announces expanded collaboration with Amgen within companion... Mar 24 2015
Dako, an Agilent Technologies Company, announces expanded collaboration with Amgen within companion... Mar 24 2015
Agilent Technologies Announces Cash Dividend of 10 Cents per Share Mar 18 2015
Daniel K. Podolsky, M.D., of University of Texas Southwestern Medical Center, to Join Agilent... Mar 18 2015
AGILENT TECHNOLOGIES INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Mar 18 2015
Agilent Technologies Announces Cash Dividend of 10 Cents per Share Mar 18 2015
Daniel K. Podolsky, M.D., of University of Texas Southwestern Medical Center, to Join Agilent... Mar 18 2015
Agilent Technologies Announces New CEO Mike McMullen Mar 18 2015
Agilent Technologies Announces New CEO Mike McMullen Mar 18 2015
S&P 500 companies with the largest off-balance sheet tax liabilities Mar 17 2015
AGILENT TECHNOLOGIES INC Financials Mar 17 2015
Agilent Technologies Boosts Productivity of Biopharmaceutical Labs with MassHunter Enhancements Mar 17 2015
Agilent Technologies Receives Innovation Award for Multiple Heart-Cutting Solution Mar 17 2015
Coverage initiated on Agilent by UBS Mar 10 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK